SEC Form 4 · accession 0001859453-26-000010

Vera Therapeutics, Inc. · VERA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Marshall Fordyce

Officer — PRESIDENT AND CEO · Director

Period of report

Jul 7, 2026

Accepted (ET)

Jul 9, 2026 · 4:45 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001831828

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A Common Stock^F2	Jul 7, 2026	S	1,000	$40.7762	D	197,244	D
Class A Common Stock^F3	Jul 7, 2026	S	32,550	$42.0736	D	164,694	D
Class A Common Stock^F4	Jul 7, 2026	S	10,500	$42.8578	D	154,194	D
Class A Common Stock^F5	Jul 7, 2026	S	2,200	$43.5947	D	151,994	D
Class A Common Stock	holding	—	—		—	122,949	I	By GRAT
Class A Common Stock	holding	—	—		—	99,081	I	By Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.